Shugaku Takeda

Author PubWeight™ 16.56^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.	Eur Urol	2012	3.20
2	Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.	Clin Cancer Res	2013	2.26
3	A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.	Cancer Res	2011	1.74
4	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.	Clin Cancer Res	2014	1.57
5	Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.	Nature	2010	1.29
6	PUMA and BIM are required for oncogene inactivation-induced apoptosis.	Sci Signal	2013	1.28
7	Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs.	Dev Cell	2013	1.01
8	Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia.	Cell Cycle	2007	1.00
9	Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.	Cancer Res	2010	1.00
10	Medea SUMOylation restricts the signaling range of the Dpp morphogen in the Drosophila embryo.	Genes Dev	2008	0.96
11	Reverse genetic analyses of gamete-enriched genes revealed a novel regulator of the cAMP signaling pathway in Dictyostelium discoideum.	Mech Dev	2005	0.81
12	Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription.	J Clin Invest	2015	0.76